Arcadia Biosciences, Inc.
RKDA
$3.46
$0.20196.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 56.50% | 18.41% | 0.69% | 1.87% | 4.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.50% | 18.41% | 0.69% | 1.87% | 4.44% |
| Cost of Revenue | 1,886.11% | 26.87% | -5.02% | 4.30% | -111.92% |
| Gross Profit | -29.52% | 3.42% | 6.94% | -11.89% | 83.94% |
| SG&A Expenses | 56.60% | 20.32% | 29.36% | -21.67% | -53.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.58% | 22.34% | 20.90% | -16.35% | -56.28% |
| Operating Income | -126.06% | -25.98% | -38.93% | 22.13% | 70.47% |
| Income Before Tax | -805.39% | -84.98% | -41.38% | 73.67% | 85.95% |
| Income Tax Expenses | 14.29% | -- | -- | -- | -46.15% |
| Earnings from Continuing Operations | -793.14% | -84.98% | -41.36% | 73.67% | 85.79% |
| Earnings from Discontinued Operations | 98.88% | 77.70% | 66.24% | -- | -109.15% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -100.00% |
| Net Income | -42.45% | 37.20% | 28.92% | 74.18% | 32.78% |
| EBIT | -126.06% | -25.98% | -38.93% | 22.13% | 70.47% |
| EBITDA | -139.09% | -34.02% | -43.19% | 22.02% | 71.59% |
| EPS Basic | -42.11% | 37.40% | 28.49% | 83.61% | 66.74% |
| Normalized Basic EPS | -1,913.96% | -84.38% | -167.73% | 83.58% | 93.90% |
| EPS Diluted | -42.11% | 37.40% | 28.49% | 83.61% | 66.74% |
| Normalized Diluted EPS | -1,913.96% | -84.38% | -167.73% | 83.58% | 93.90% |
| Average Basic Shares Outstanding | 0.24% | 0.32% | 0.32% | 57.53% | 102.12% |
| Average Diluted Shares Outstanding | 0.24% | 0.32% | 0.32% | 57.53% | 102.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |